Boston Scientific Completes Enrollment In Clinical Trial Evaluating Next-Generation Nitinol Stent To Treat Iliac Artery Disease
Links shared publicly online about this topic.
- 588total visits
Boston Scientific Completes Enrollment In Clinical Trial Evaluating Next-Generation Nitinol Stent To Treat Iliac Artery Disease
Boston Scientific Corporation (NYSE: BSX) announced that it has completed enrollment in the ORION clinical trial, which is designed to evaluate the Company's EPIC™ Self-Expanding Nitinol Ste
View full resource at medicalnewstoday.com
Tags: Circulation, Disease and Condition, Clinical Trial, disease
Most Recently Shared on January 11, 2011 at 8:39 pm By:
Boston Scientific Completes Enrollment In Clinical Trial Evaluating Next-Generation Nitinol Stent To Treat Iliac... http://bit.ly/eanHFg
Also Shared By:
Advertisement
MNT Pharma News
@mnt_pharma
Boston Scientific Completes Enrollment In Clinical Trial Evaluating Next-Generation Nitinol Stent To Treat Iliac Arter... http://mnt.to/3PR6
1 year ago...